- Altendorf T, Gering I, Santiago-Schübel B, Aghabashlou Saisan S, Tamgüney G, Tusche M, Honold D, Schemmert S, Hoyer W, Mohrlüder J, Willbold D
Stabilization of monomeric Tau protein by all D-enantiomeric peptide ligands as therapeutic strategy for Alzheimer's disease and other tauopathies
Int J Mol Sci 24, 2161 (2023)
https://doi.org/10.3390/ijms24032161
- Kutzsche J, Schemmert S, Bujnicki T, Zafiu C, Halbgebauer S, Kraemer-Schulien V, Pils M, Blömeke L, Post J, Kulawik A, Jürgens D, Rossberg WM, Hümpel M, Bannach O, Otto M, Araujo JA, Willuweit A, Willbold D.
Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - A model of sporadic Alzheimer's disease
Heliyon 29;9(8):e18443, (2023)
https://pubmed.ncbi.nlm.nih.gov/37609390/
- Kass B, Schemmert S, Zafiu C, Pils M, Bannach O, Kutzsche J, Bujnicki T, Willbold D.
Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo.
Cell Rep Med. 3(5):100630, (2022)
https://doi.org/10.1016/j.xcrm.2022.100630
- Törner R, Kupreichyk T, Gremer L, Debled EC, Fenel D, Schemmert S, Gans P, Willbold D, Schoehn G, Hoyer W, Boisbouvier J
Structural basis for the inhibition of IAPP fibril formation by the co-chaperonin prefoldin
Nat Commun 13, 2363 (2022)
https://doi.org/10.1038/s41467-022-30042-y
- Camargo LC, Honold D, Bauer R, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A, Schemmert S.
Sex-Related Motor Deficits in the Tau-P301L Mouse Model
Biomedicines 9(9):1160, (2021)
https://pubmed.ncbi.nlm.nih.gov/34572348/
- Camargo LC, Schöneck M, Sangarapillai N, Honold D, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Schemmert S, Willuweit A
PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease
Int J Mol Sci. 22(13):706, (2021)
https://pubmed.ncbi.nlm.nih.gov/34209113/
- Schemmert S, Camargo LC, Honold D, Gering I, Kutzsche J, Willuweit A, Willbold D
n Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease
Int J Mol Sci. 22(12):6553, (2021)
https://pubmed.ncbi.nlm.nih.gov/34207233/
- Elfgen A, Santiago-Schübel B, Hupert M, Schemmert S, Schartmann E, Tusche M, Gering I, Zafiu C, Kutzsche J.
Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid
Eur J Pharm Sci. , (2020)
https://pubmed.ncbi.nlm.nih.gov/33035662/
- Schemmert S, Schartmann E, Honold D, Zafiu C, Ziehm T, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D.
Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
Neurobiol Dis. 124, 36-45 (2019)
https://www.sciencedirect.com/science/article/pii/S0969996118307320
- Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D.
Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.
Mol Neurobiol. 56(3):, 2211-2223 (2019)
https://10.1007/s12035-018-1209-3
https://www.ncbi.nlm.nih.gov/pubmed/30003517
- Dunkelmann T, Teichmann K, Ziehm T, Schemmert S, Frenzel D, Tusche M, Dammers C, Jürgens D, Langen KJ, Demuth HU, Shah NJ, Kutzsche J, Willuweit A, Willbold D
Aβ oligomer eliminating compounds interfere successfully with pEAβ (3–42) induced motor neurodegenerative phenotype in transgenic mice
Neuropeptides 67, 27-35 (2018)
https://doi.org/10.1016/j.npep.2017.11.011
https://www.sciencedirect.com/science/article/pii/S0143417917301531
- Dunkelmann T, Schemmert S, Honold D, Teichmann K, Butzküven E, Demuth HU, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.
Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.
J Alzheimers Dis. 63(1), 115-130 (2018)
https://10.3233/JAD-170775
https://www.ncbi.nlm.nih.gov/pubmed/29578479
- Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.
In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.
J Alzheimers Dis 64(3), 859-873 (2018)
https://10.3233/JAD-180165
https://www.ncbi.nlm.nih.gov/pubmed/29966196
- Hupert M, Elfgen A, Schartmann E, Schemmert S, Buscher B, Kutzsche J, Willbold D, Santiago-Schübel B
Development and Validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma
Journal of Chromatography B 1073, 123-129 (2017)
https://doi.org/10.1016/j.jchromb.2017.12.009
https://www.sciencedirect.com/science/article/pii/S1570023217316562
- Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D.
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
Molecules 22(10), (2017)
http://10.3390/molecules22101693
https://www.ncbi.nlm.nih.gov/pubmed/28994710
- Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.
Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
Eur J Pharm Sci. 17, 0928-0987 (2017)
https://doi.org/10.1016/j.ejps.2017.12.005
https://www.ncbi.nlm.nih.gov/pubmed/29225107
- van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann E, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold D.
The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
Sci Rep. 7, 16275 (2017)
https://doi.org/10.1038/s41598-017-16565-1
https://www.nature.com/articles/s41598-017-16565-1
Responsible for the content:
